Summary

The first single-tablet regimen containing an integrase inhibitor for the treatment of human immunodeficiency virus demonstrated high rates of virologic suppression, safety, and tolerability at 144 weeks in treatment-naïve patients. This article presents the results of the prespecified pooled analysis from 2 double-blind, active-control phase 3 studies of first-line treatment.